Windlas Biotech Limited has informed the Exchange about Amendments to Sub-clause 3.2 of the Windlas Plan 2025 ( Plan )
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech's Nomination and Remuneration Committee, via a circular resolution dated August 24, 2025, approved clarificatory amendments to Sub-clause 3.2 of the company's 'Windlas Plan 2025' employee stock unit scheme. The original shareholder-approved cap of 3,15,000 Units per employee per year remains unchanged, but the amendment adds a new per-grant sub-limit of 2,09,590 Units per eligible employee per year. It also introduces a requirement that any grant equal to or exceeding 1% of the company's issued capital must comply with Sub-clause 3.3 and other applicable laws. No Units have been issued under the Plan so far, and the changes are described as purely clarificatory, aligning the scheme with SEBI's SBEB Regulations, 2021 disclosure requirements.
This is a procedural/clarificatory amendment with no change to the overall shareholder-approved grant limits, so it is unlikely to materially affect shareholders. However, the new per-grant cap and the 1% of issued capital threshold add guardrails that could modestly dilute future equity if the Plan is actively used to reward employees.